Flexible Stenting Solutions (FSS; Eatontown, New Jersey) has submitted an Investigational Device Exemption application to the FDA for its FlexStent Femoropopliteal SE Stent System for the treatment of peripheral artery disease in the superficial femoral and popliteal arteries. This next generation femoropopliteal stent and delivery system can significantly improve patient care in the high-growth peripheral vascular segment. The fully connected flexible FlexStent has coupled technology with clinical needs by providing what the company said is "a highly durable and fatigue resistant stent."

• IDEV Technologies (Houston) said the FDA has approved an investigational device exemption for a multi-center clinical trial of its Supera stent, a novel stent platform designed for the treatment of peripheral artery disease in the superficial femoral artery (SFA). The objective of the trial is to demonstrate the safety and effectiveness of the Supera Interwoven Self-Expanding Nitinol Stent in treating subjects with obstructive SFA disease. Supera has demonstrated superior properties in engineering tests compared to nitinol laser cut slotted tube stents resulting in greater than four times the radial strength and 360% stronger crush resistance.

• InterCure (New York) said that RESPeRATE, its blood pressure treatment device, is now being sold in 100 Boots Pharmacy stores throughout the UK. The device uses the body's natural tendency to follow external rhythms, interactively guiding the user to effortlessly reduce their breathing rate to a "therapeutic zone" of less than 10 breaths per minute. The breathing exercises with RESPeRATE relax the constricted muscles surrounding the small blood vessels, allowing the blood to flow more freely and yielding a significant and lasting reduction of blood pressure within weeks.

• L.I.T. Surgical (Chicago) has introduced the ONE Headlit, a new surgical headlight that delivers bright light in a tether-free configuration allowing freedom of movement in a low-maintenance, lightweight design. ONE Headlit uses L.I.T. Surgical's Optical Navigation Engine (ONE) technology that delivers more than 10,000 hours of consistently bright, white, better-than-xenon quality of light in a battery-powered device. The tether-free design allows surgeons to move freely around the OR while providing superior illumination, and it requires virtually no maintenance, resulting in significant economic advantages over conventional technology.

• Oxygen Biotherapeutics (Costa Mesa, California) said it will move ahead with a line of gels based on Oxycyte. The first and most basic gel based on Oxycyte will be formulated to enhance its topical cosmetic properties. Oxycyte is the company's perfluorocarbon (PFC) therapeutic oxygen carrier. The company intends to market the first Oxycyte Gel as a cosmetic which provides a moist, oxygen-rich environment for the skin. No therapeutic claim for healing will be made for this baseline, cosmetically-formulated Oxycyte Gel.

• Power3 Medical Products (Houston) said it is moving forward with its program to commercialize its diagnostic blood tests NuroPro and BC-SeraPro. "After successfully taking the necessary strategic steps to financially prepare for commercialization, I am happy to report that Power3 is on-track and on-plan for the intended launch of our diagnostic blood tests for Alzheimer's and Parkinson's diseases (NuroPro) and for Breast Cancer (BC-SeraPro)," said chairman and chief scientific officer Ira Goldknopf.

• Quantia Communications (Newton, Massachusetts) said that its rich media, interactive physician community is now available for free on the iPhone App Store, as a complement to its existing presence on the web, Blackberry smartphones and Windows Mobile devices. The new QuantiaMD application was specifically designed to take advantage of the unique functionality of the iPhone and the iPod touch. Physicians can easily launch interactive presentations and clinical updates, respond to surveys, participate in case studies, complete CME activities, quickly post and review comments and ratings, and even refer content to peers. Quantia developed the native application, with its adept handling of rich media and interactive content, to give physicians a valuable, educational and entertaining mobile experience.

• Quest Diagnostics (Madison, New Jersey) said its ClariSure microarray-based comparative genomic hybridization (aCGH) postnatal test is now available for testing on patients in the state of New York. The state has approved the use of the ClariSure aCGH postnatal test as an aid in detecting copy-number chromosomal abnormalities implicated in dozens of medical conditions, including mental retardation, birth defects, and autism spectrum and developmental disorders, which conventional laboratory tests may fail to detect. Scientists have validated the ClariSure test's ability to use a single blood specimen to identify chromosomal abnormalities associated with dozens of disorders, including Down, cri du chat, DiGeorge and Williams syndromes. A positive result may be confirmed using a fluorescence in situ hybridization (FISH) methodology.

• Welch Allyn Lighting Products (Skaneateles Falls, New York) reported the introduction of the ProXenon Surgical Headlight Camera, an accessory to its flagship ProXenon 350 Headlight System. The ProXenon Surgical Headlight Camera provides a video signal to facilitate recording and displaying surgical procedures on video monitors within the surgical suite. Surgeons often record procedures to archive the footage or use it later as presentation material. The ProXenon Surgical Headlight Camera could also improve efficiency in the operating room during minimal-incision, deep-tissue surgeries by allowing other members of the surgical team to view the surgeon's progress throughout the procedure.

No Comments